Clinical Trial

A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population

Study acronym: MASH
Completed
View on ClinicalTrials.gov →
Summary
The purpose of this study is to collect information for scientific research and to better understand awareness and to understand overall risk awareness, diagnoses and treatment related to liver related diseases. The study aims to collect valid responses through online questionnaires from the participants. This study is a survey-based study without collection of laboratory data. It will take the participant 25 minutes to complete the survey. The study is not related to any specific treatment options or pharmaceutical product.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-23; most recent amendment 2026-03-10.
Status change: Enrolling by Invitation → Completed 2026-03-10
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-11-07
Trial Details
NCT Number NCT07201831
Lead Sponsor Novo Nordisk A/S
Conditions Metabolic Dysfunction-associated Steatohepatitis (MASH)
Enrollment 1,330 participants
Start Date 2025-10-02
Primary Completion 2026-01-17 (estimated)
Study Completion 2026-01-17 (estimated)
Updated on ClinicalTrials.gov 2026-03-12